How do the biosimilar markets in the US and Europe compare?

Posted 19/02/2021

Authors discuss how the biosimilar markets in the US and Europe compare in a report produced for the Biosimilars Council [1].

Canada approves infliximab biosimilar Remsima SC Biosimilars/News | Posted 19/02/2021
Improving stakeholder understanding about biosi... Biosimilars/Research | Posted 19/02/2021
Innovent starts phase II trial for ipilimumab c... Biosimilars/News | Posted 19/02/2021
Adherence improves long-term prognosis and medi... Generics/Research | Posted 19/02/2021
Biosimilar approvals and patent litigation in t... Biosimilars/General | Posted 19/02/2021
Problems with the tiered pricing policy for gen... Policies & Legislation | Posted 19/02/2021
Interchangeability, naming and pharmacovigilanc... Biosimilars/Research | Posted 12/02/2021
EMA recommends approval of adalimumab biosimila... Biosimilars/News | Posted 12/02/2021
Improving the understanding of biosimilars thro... Biosimilars/Research | Posted 12/02/2021
Anti-competitive strategic patenting by pharmac... Generics/Research | Posted 12/02/2021
Canada approves insulin aspart biosimilar Trurapi Biosimilars/News | Posted 12/02/2021
Regulatory issues related to quality of biosimi... Biosimilars/Research | Posted 05/02/2021
China extends indications for adalimumab and be... Biosimilars/News | Posted 05/02/2021
Understanding and minimizing injection-site pai... Biosimilars/Research | Posted 05/02/2021
Canada approves three teriparatide biosimilars... Biosimilars/News | Posted 05/02/2021
Biocon and Lupin launch generic tacrolimus caps... Generics/News | Posted 05/02/2021
Top 10 most read GaBI Online articles in 2020 Pharma News | Posted 29/01/2021
Clinical evidence for interchangeability of bio... Biosimilars/Research | Posted 29/01/2021
EMA recommends approval of insulin aspart biosi... Biosimilars/News | Posted 29/01/2021
FDA approves rituximab biosimilar Riabni Biosimilars/News | Posted 29/01/2021
New generics company to offer low-cost versions... Generics/General | Posted 29/01/2021
EMA and EU medicines regulatory joint five-year... Policies & Legislation | Posted 29/01/2021
Biosimilars and lack of resources Biosimilars/Research | Posted 22/01/2021
EMA recommends approval of adalimumab and insul... Biosimilars/News | Posted 22/01/2021
How organizations worldwide are producing HTA r... Biosimilars/Research | Posted 22/01/2021
Generics applications under review by EMA – Jan... Generics/General | Posted 22/01/2021
Canada approves heparin biosimilars Redesca and... Biosimilars/News | Posted 22/01/2021
Samsung biosimilars: denosumab clinical trials... Biosimilars/General | Posted 22/01/2021
Biosimilars and availability of reference products Biosimilars/Research | Posted 15/01/2021
Biosimilars applications under review by EMA –... Biosimilars/General | Posted 15/01/2021
EC approval for pegfilgrastim biosimilar Nyvepria Biosimilars/News | Posted 15/01/2021
Influence of local policy measures and practice... Biosimilars/Research | Posted 15/01/2021
US guidance on proprietary names Guidelines | Posted 15/01/2021
Positive phase III results for sintilimab plus... Biosimilars/Research | Posted 15/01/2021
Perspectives of prescribing practices in public... Generics/Research | Posted 15/01/2021
Regulatory challenges with biosimilars Biosimilars/Research | Posted 08/01/2021
China approves adalimumab copy biological HLX03 Biosimilars/News | Posted 08/01/2021


FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015